Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lactoplantibacillus plantarum CECT7527** is a specific probiotic bacterial strain originally classified as *Lactobacillus plantarum* CECT 7527 and now reclassified under *Lactoplantibacillus*. It has been studied primarily for its role in reducing cholesterol levels as part of a multi-strain probiotic approach. The mechanism of action includes high bile salt hydrolase activity, which leads to breakdown of bile, increased bile acid deconjugation, and subsequent increased cholesterol utilization for new bile salt synthesis. The strain also directly assimilates cholesterol from its environment and can bind cholesterol to its cell surface. It is effective at surviving gastrointestinal conditions and adhering to intestinal cells, indicating its suitability as an oral probiotic. Developed and manufactured by AB-BIOTICS, it has been included individually and in combination with CECT7528 and CECT7529 for clinical evaluation aimed at hypercholesterolemia and cardiovascular risk reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactoplantibacillus plantarum CECT7527.